Tekturna - 2007 FDA approvals

Drug: Tekturna (aliskiren)
Indication: Hypertension
Company: Novartis
Approval Date: March 5, 2007

Scoop: Tekturna is the first in a new class of drugs called direct renin inhibitors, which target an enzyme responsible for triggering a process that can contribute to high blood pressure. Novartis hopes that Tekturna will eventually replace the company's blockbuster drug Diovan--which does $4.22 billion in annual sales--when the patent on that drug expires.

More news:
FDA approves Novartis' Tekturna. Report

Image: Tekturna packaging

Tekturna - 2007 FDA approvals

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.